| Burkes, Ronald L |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Active, not recruiting | 1/2 | 115 | Europe, Canada, US | GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab | Nouscom SRL, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 04/25 | 11/26 | | |
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) |
|
|
| Recruiting | N/A | 1000 | Canada | Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs) | University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc. | Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation | 12/25 | 12/25 | | |
NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer |
|
|
| Active, not recruiting | N/A | 889 | Europe, Canada, US, RoW | exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing | Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast | Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise | 12/29 | 12/30 | | |
| Li, Hong |
REPOSE-2, NCT05728775: REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry |
|
|
| Recruiting | 4 | 7188 | RoW | Remimazolam, Propofol | Nanfang Hospital of Southern Medical University | Anesthesia, Surgery-Complications | 12/24 | 12/27 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
| Recruiting | N/A | 1250 | RoW | EEG(Electroencephalogram) change | Air Force Military Medical University, China | Aging, Postoperative Cognitive Dysfunction, EEG With Periodic Abnormalities | 03/23 | 04/23 | | |
NCT06308627: A One-year Trajectory of Depression Status Changes in Older Adults With MCI and SD: a Longitudinal Cohort Study |
|
|
| Completed | N/A | 466 | RoW | | Fujian Medical University | Mild Cognitive Impairment, Subthreshold Depression, Older Adults | 08/24 | 08/24 | | |
NCT05521295: Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome |
|
|
| Recruiting | N/A | 3600 | RoW | no intervention | Shengjing Hospital, Beijing Institutes of Life Science, Chinese Academy of Sciences | Infertility, Microbiome | 09/23 | 09/24 | | |
REMAIN-2, NCT05962125: The Role of Periodic Alveolar Recruitment Maneuvers in Intraoperative Protective Ventilation |
|
|
| Completed | N/A | 75 | RoW | periodic alveolar recruitment maneuvers, positive end-expiratory pressure | Sixth Affiliated Hospital, Sun Yat-sen University | Mechanical Power, Alveolar Recruitment Maneuvers, Protective Ventilation, Postoperative Pulmonary Complications | 11/23 | 12/23 | | |
NCT05442125: First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization |
|
|
| Recruiting | N/A | 1146 | RoW | Using DNA methylome to select embryos, Using morphologic score to select embryos | Shandong University, RenJi Hospital, Reproductive & Genetic Hospital of CITIC-Xiangya, Nanjing Maternity and Child Health Care Hospital, ShangHai Ji Ai Genetics & IVF Institute, Suzhou Municipal Hospital, The First Hospital of Jilin University, Sir Run Run Shaw Hospital, The Affiliated Hospital Of Guizhou Medical University, The Second Hospital of Hebei Medical University, Third Affiliated Hospital of Zhengzhou University, Ruijin Hospital, International Peace Maternity and Child Health Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Hainan Medical University, The First Affiliated Hospital of Anhui Medical University, Fujian Maternity and Child Health Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital with Nanjing Medical University, 900 th Hospital of Joint Logistics Support Force, Guangzhou Womenand Children's Medical Center, Changhai Hospital, Shenzhen Maternity & Child Healthcare Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Jining Medical University, Siriraj hospital, Mahidol university, Thailand | Reproductive Techniques, Assisted, DNA Methylation | 06/24 | 05/25 | | |
NDURE2, NCT04030130: Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC |
|
|
| Completed | N/A | 176 | US | NDURE | Medical University of South Carolina, National Cancer Institute (NCI) | Squamous Cell Carcinoma of Head and Neck | 12/23 | 01/24 | | |
NCT06706739: A Trial of Combined Subthreshold Depression in Older Adults With Mild Cognitive Impairment Participating in Art Games |
|
|
| Recruiting | N/A | 80 | RoW | Online art game intervention group | Fujian Medical University | Mild Cognitive Impairment, Subthreshold Depression | 12/24 | 12/24 | | |
| Completed | N/A | 1060 | RoW | periodic lung recruitment maneuvers | Sixth Affiliated Hospital, Sun Yat-sen University | Postoperative Complications, Abdominal Surgery, Intraoperative Mechanical Ventilation | 09/24 | 11/24 | | |
NCT04989153: Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer |
|
|
| Recruiting | N/A | 5000 | RoW | pepsinogen | Second Affiliated Hospital, School of Medicine, Zhejiang University, Jilin City People's Hospital, No. 924 Hospital of the People's Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, Affiliated Hospital of Southwest Medical University, Zhongshan Hospital Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine, Changhai Hospital | Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection | 12/22 | 12/23 | | |
| Thaler, Josef |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Recruiting | N/A | 3000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company | Breast Cancer, Breast Carcinoma, Breast Tumor | 06/25 | 06/25 | | |
ABCSG C08, NCT03822572: -Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer |
|
|
| Recruiting | N/A | 788 | Europe | endurance exercise, control | Austrian Breast & Colorectal Cancer Study Group, Oberösterreichische Krebshilfe | Colorectal Carcinoma | 12/26 | 12/26 | | |
| Lordick, Florian |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04460352 / 2020-000149-15: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer |
|
|
| Recruiting | 3 | 1020 | Europe, Canada | Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Neoadjuvant chemotherapy, Esophagectomy, Neoadjuvant radiotherapy (arm B), Neoadjuvant Platin-Taxane Regimen (alternative 1), Cisplatin, paclitaxel, Platinum-Fluoropyrimidine Regimens (alternative 2a), Oxaliplatin, calcium folinate, 5-fluorouracil, Platinum-Fluoropyrimidine Regimens (alternative 2b) | Karolinska University Hospital, University of Leipzig, The Swedish Research Council | Esophageal Squamous Cell Carcinoma | 09/26 | 12/31 | | |
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy |
|
|
| Active, not recruiting | 2/3 | 429 | Europe | FOLFIRI, Ramucirumab, Paclitaxel | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Advanced Gastric or EGJ Cancer | 12/25 | 12/25 | | |
VESTIGE, NCT03443856: Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence |
|
|
| Active, not recruiting | 2 | 197 | Europe, RoW | Nivolumab and Ipilimumab, chemotherapy | European Organisation for Research and Treatment of Cancer - EORTC | Gastric and Esophagogastric Junction Adenocarcinoma | 12/23 | 06/26 | | |
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma |
|
|
| Not yet recruiting | 1/2 | 36 | Europe | Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo | Esophagogastric Adenocarcinoma | 12/27 | 12/27 | | |
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma |
|
|
| Active, not recruiting | 1/2 | 56 | Europe | Sacituzumab govitecan, Trodelvy | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences | Esophagogastric Adenocarcinoma | 02/27 | 03/27 | | |
NCT04675138: Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care |
|
|
| Recruiting | N/A | 1000 | Europe, Japan, RoW | No intervention will be provided to the subject | National University Hospital, Singapore | Gastric Cancer, Esophageal Cancer, Esophagogastric Junction Cancer | 12/24 | 12/24 | | |
| Recruiting | N/A | 900 | Europe | Routine care as per site standard | iOMEDICO AG | Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 12/24 | | |
| Cubero, Daniel IG |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 1/2 | 60 | RoW | IMX-110 combined with Tislelizumab, One Arm | Immix Biopharma, Inc., BeiGene, Novartis | Advanced Solid Tumor | 01/24 | 01/24 | | |
| Yu, Xueqing |
AURORA, NCT03214731: Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis |
|
|
| Recruiting | 4 | 90 | RoW | Artesunate, Art, placebo | Sun Yat-sen University, The First People's Hospital of Yunnan, The First Affiliated Hospital of Nanchang University, General Hospital of Ningxia Medical University, First Affiliated Hospital of Fujian Medical University, Shenzhen Second People's Hospital, The Third Xiangya Hospital of Central South University, Tongji Hospital | Lupus Nephritis | 09/22 | 09/22 | | |
LUMINA, NCT03200210: Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients |
|
|
| Recruiting | 4 | 548 | RoW | Febuxostat, Febuxostat Tablets, Placebo | Sun Yat-sen University | Hyperuricemia | 12/22 | 12/22 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
NCT06016036: SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease |
|
|
| Completed | 3 | 156 | RoW | SAL-0951, SAL-0951 group, Placebo, Placebo phase | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Renal Anemia in Non-dialysis Chronic Kidney Disease | 10/21 | 02/22 | | |
| Recruiting | 3 | 486 | RoW | SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo | Shanghai Hengrui Pharmaceutical Co., Ltd. | Secondary Hyperparathyroidism | 06/25 | 07/25 | | |
NCT05663411: A Study of SHR6508 in Secondary Hyperparathyroidism |
|
|
| Active, not recruiting | 2 | 75 | RoW | SHR6508, Cinacalcet | Shanghai Hengrui Pharmaceutical Co., Ltd. | Secondary Hyperparathyroidism | 10/23 | 11/23 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT06676631: NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis |
|
|
| Not yet recruiting | 1 | 18 | NA | NK 010 or NK042, NK010 or NK042 infusion, Rituximab, RTX | Guangdong Provincial People's Hospital | Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis | 12/26 | 12/27 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
| Recruiting | N/A | 903 | RoW | Dialysis modality | Sun Yat-sen University | End Stage Renal Disease on Dialysis, Peritoneal Dialysis, Hemodialysis | 12/21 | 12/21 | | |
NCT05190848: Correlation of Microbiome and Metabonomics With IgA Nephropathy |
|
|
| Recruiting | N/A | 600 | RoW | | Guangdong Provincial People's Hospital | IgA Nephropathy | 12/24 | 12/24 | | |
| Recruiting | N/A | 10000 | RoW | No intervention | Sun Yat-sen University | IgA Nephropathy | 12/26 | 12/26 | | |
NCT03001973: High Quality Evidence of Chinese Lupus Nephritis (HELP) |
|
|
| Recruiting | N/A | 5000 | RoW | No Intervention | Sun Yat-sen University | Lupus Nephritis | 12/26 | 12/26 | | |
NCT02989298: Peritoneal Dialysis Registration System (PERSIST) |
|
|
| Recruiting | N/A | 10000 | RoW | No intervention | Sun Yat-sen University | ESRD, Disorders Associated With Peritoneal Dialysis | 12/26 | 12/26 | | |
| Recruiting | N/A | 30000 | RoW | No intervention | Sun Yat-sen University | Haemolyses and Related Conditions | 12/26 | 12/27 | | |
| Recruiting | N/A | 5000 | RoW | No intervention | Sun Yat-sen University | Nephrotic Syndrome | 12/26 | 12/28 | | |
NCT05188885: A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases |
|
|
| Recruiting | N/A | 90000 | RoW | | Guangdong Provincial People's Hospital | Chronic Kidney Disease | 12/26 | 12/28 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Xiangdong, Guan |
NCT04904289: Early Recognition and Dynamic Risk Warning System of Multiple Organ Dysfunction Syndrome Caused by Sepsis |
|
|
| Recruiting | N/A | 60000 | RoW | All intervention of real world | Sun Yat-sen University | Sepsis, MODS | 09/23 | 12/23 | | |
| Liu, Tao Chun |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
NCT05277987: An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects |
|
|
| Recruiting | 1 | 18 | RoW | HEC-016(0.5×10^6 CAR-T Cells), HEC-016(0.5×10^6.5 CAR-T Cells), HEC-016(0.5×10^7 CAR-T Cells) | Shenzhen Fifth People's Hospital | CAR T-Cell Therapy | 03/25 | 03/25 | | |
NCT03862495: Genital CT Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Pilot RCT |
|
|
| Completed | N/A | 200 | RoW | C. trachomatis and N. gonorrhoeae, Roche Cobas Z480, Azithromycin, Zithromax, Zmax, Partner notification and treatment | University of North Carolina, Chapel Hill, Southern Medical University, China | Chlamydia Trachomatis Infection | 03/24 | 03/24 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Not yet recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/26 | 05/31 | | |
